KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biocryst Pharmaceuticals (BCRX) Leases (2020 - 2025)

Biocryst Pharmaceuticals filings provide 6 years of Leases readings, the most recent being $2.7 million for Q4 2025.

  • On a quarterly basis, Leases fell 67.06% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a 67.06% decrease, with the full-year FY2025 number at $2.7 million, down 67.06% from a year prior.
  • Leases hit $2.7 million in Q4 2025 for Biocryst Pharmaceuticals, down from $7.7 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $11.4 million in Q3 2023 to a low of $2.7 million in Q4 2025.
  • Median Leases over the past 5 years was $7.7 million (2025), compared with a mean of $7.4 million.
  • Biggest five-year swings in Leases: soared 104.67% in 2023 and later plummeted 67.06% in 2025.
  • Biocryst Pharmaceuticals' Leases stood at $6.5 million in 2021, then plummeted by 34.46% to $4.2 million in 2022, then skyrocketed by 104.67% to $8.7 million in 2023, then decreased by 7.15% to $8.1 million in 2024, then plummeted by 67.06% to $2.7 million in 2025.
  • The last three reported values for Leases were $2.7 million (Q4 2025), $7.7 million (Q3 2025), and $7.9 million (Q2 2025) per Business Quant data.